NAVCO Pharmaceuticals Inc. (TSXV:NAV)

NAVCO Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Revenue	-	-	-	0.06	0.02
Revenue Growth (YoY)	-	-	-	278.32%	-
Gross Profit	-	-	-	0.06	0.02
Selling, General & Admin	0.15	0.87	1.4	0.47	0.5
Amortization of Goodwill & Intangibles	-	0.05	0.01	0.01	0
Operating Expenses	0.15	0.94	1.44	0.51	0.53
Operating Income	-0.15	-0.94	-1.44	-0.45	-0.51
Interest Expense	-0.01	-0.02	-0.01	-0.01	-0.01
Other Non Operating Income (Expenses)	-0.02	-0.03	-0.03	-	-
EBT Excluding Unusual Items	-0.18	-0.99	-1.48	-0.47	-0.53
Asset Writedown	-0.73	-0.73	-	-	-
Other Unusual Items	-	-	-0.67	-	-
Pretax Income	-0.92	-1.72	-2.15	-0.47	-0.53
Net Income	-0.92	-1.72	-2.15	-0.47	-0.53
Net Income to Common	-0.92	-1.72	-2.15	-0.47	-0.53
Shares Outstanding (Basic)	57	52	30	21	14
Shares Outstanding (Diluted)	57	52	30	21	14
Shares Change (YoY)	0.02%	72.37%	41.49%	47.34%	-
EPS (Basic)	-0.02	-0.03	-0.07	-0.02	-0.04
EPS (Diluted)	-0.02	-0.03	-0.07	-0.02	-0.04
Free Cash Flow	-0.04	-0.25	-1.78	-0	-0.31
Free Cash Flow Per Share	-0.00	-0.01	-0.06	-	-0.02
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-766.48%	-3309.64%
Profit Margin	-	-	-	-791.92%	-3389.75%
Free Cash Flow Margin	-	-	-	-7.72%	-2027.27%
EBITDA	-0.12	-0.88	-1.4	-0.42	-0.49
D&A For EBITDA	0.04	0.06	0.04	0.03	0.02
EBIT	-0.15	-0.94	-1.44	-0.45	-0.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.